Compare Star Bulk Carriers Corp (SBLK) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Star Bulk Carriers Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Star Bulk Carriers Corp trades at $31.1 (market cap $3.46B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 38.7× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays a 6.06% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| SBLK | VRTX | |
|---|---|---|
Market Cap | $3.46B | $134.06B |
Sector | Industrials | Health |
52-Week High | $32.42 | $557.96 |
52-Week Low | $16.79 | $376.62 |
Enterprise Value | $4.14B | $128.18B |
Dividend Yield | 6.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Star Bulk Carriers (SBLK) trades at $31.02, down 4.32% on the day, with strong technical indicators showing a bullish trend. The company demonstrates robust fundamentals with Q2 2026 EPS of $1.21 beating expectations by 27%, maintaining a three-quarter earnings beat streak. Valuation metrics appear reasonable with P/E of 12.16 and P/B of 1.38, while profitability remains strong with 23.87% net income margin. Recent developments include a parallel listing on Euronext Athens and consistent dividend payments.
SBLK presents a compelling investment case with strong earnings momentum, attractive dividend yield, and positive analyst sentiment. However, risks include shipping rate volatility and geopolitical tensions affecting global trade. The stock's current technical strength and fundamental performance suggest potential upside, though investors should monitor industry cyclicality and the company's execution on its growth strategy.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
